People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aminex Therapeutics, Inc. | — | Biotechnology | Series B | $34.5M | $221.4M | 2014 |
Mark Burns at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Burns on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Miller | 1 | 9 |
| Jeff Miller | 1 | 4 |
| Thomas Graham | 1 | 3 |
| Rhonda Rhyne | 1 | 2 |
| John Rosling | 1 | 2 |
| Roger Ulrich | 1 | 2 |
| Donald Mowat | 1 | 1 |
| Deyaa Adib | 1 | 1 |
| David Meeks | 1 | 1 |
| Don Dyer | 1 | 1 |
| Larry Richards | 1 | 1 |
| Stacy Hock | 1 | 1 |
| James Skaggs | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.